How do I transition a patient receiving 32 U of Levemir (insulin detemir) to Basaglar (insulin glargine)?

Transitioning from Levemir 32 Units to Basaglar

When switching from Levemir (insulin detemir) 32 units to Basaglar (insulin glargine U-100), start with 32 units of Basaglar once daily—this is a unit-for-unit conversion. 1

Direct Conversion Protocol

• Use the same total daily dose: The FDA label for Basaglar explicitly states that when changing from another insulin glargine product (100 units/mL) or from intermediate/long-acting insulins like detemir, the dose of Basaglar should match the previous basal insulin dose. 1

• Administer once daily at the same time each day: Unlike Levemir, which often requires twice-daily dosing, Basaglar provides 20-24 hour coverage and is given once daily. 2

• Expect comparable or slightly improved glycemic control: Real-world data from 2021 showed that patients converting to Basaglar required similar basal insulin doses (mean increase of only 2.1 units, which was statistically but not clinically significant), with a non-significant decrease in HbA1c of -0.14%. 3

Key Pharmacokinetic Differences to Understand

Levemir has a shorter duration of action (12-24 hours) compared to Basaglar's 20-24 hours, which is why many patients on Levemir require twice-daily dosing. 2 If your patient was taking Levemir twice daily (e.g., 16 units BID = 32 units total), consolidate to 32 units of Basaglar once daily. 1

Both insulins have similar onset (approximately 2 hours) and lack a pronounced peak, making them appropriate basal insulins. 2

Monitoring and Titration Strategy

• Increase blood glucose monitoring frequency during the transition: Check fasting glucose daily for the first 1-2 weeks. 1

• Titrate based on fasting glucose values over one week: If fasting glucose consistently exceeds target (typically 80-130 mg/dL), increase Basaglar by 10-20% or 2-4 units once or twice weekly. 4, 5

• Watch for hypoglycemia in the first 48-72 hours: Although Basaglar and Levemir have similar hypoglycemia profiles, any insulin regimen change can predispose to hypoglycemia. 1

• Adjust for patient-specific factors: Elderly patients (≥70 years) or those with renal impairment (eGFR <60 mL/min) may require a 10-20% dose reduction to minimize hypoglycemia risk. 2

Common Pitfalls to Avoid

Do not reduce the dose by 20% when switching from Levemir to Basaglar. The 20% reduction rule applies only when switching from twice-daily NPH to once-daily glargine, or from glargine U-300 to glargine U-100. 1 Research comparing detemir to glargine shows that detemir often requires 27-38% higher doses than glargine to achieve equivalent control, meaning a unit-for-unit switch from Levemir to Basaglar is conservative and safe. 6, 7, 8

Do not continue twice-daily dosing with Basaglar. Basaglar is designed for once-daily administration; splitting the dose negates its pharmacokinetic advantage and increases injection burden unnecessarily. 1

Rotate injection sites within the same anatomic region (abdomen, thigh, or deltoid) to reduce lipodystrophy risk, which can cause erratic absorption and hyperglycemia. 1

Algorithm for Dose Adjustment Post-Conversion

1. Day 1-7: Administer Basaglar 32 units once daily; monitor fasting glucose daily. 1

2. If ≥50% of fasting values are above target: Increase Basaglar by 2-4 units. 2, 4

3. If ≥2 fasting values per week are <80 mg/dL: Decrease Basaglar by 2-4 units (10-20% reduction). 2, 4

4. Repeat weekly adjustments until fasting glucose consistently reaches 80-130 mg/dL. 4, 5

5. If basal dose exceeds 0.5 units/kg/day without achieving target: Consider adding prandial insulin or a GLP-1 receptor agonist rather than further increasing basal insulin (to avoid overbasalization). 4

Special Considerations

Type 1 diabetes patients: Must continue short- or rapid-acting mealtime insulin alongside Basaglar; never discontinue prandial coverage. 1

Type 2 diabetes patients on oral agents: Continue metformin and other non-insulin medications during the transition unless contraindicated. 2

Inpatient conversions: A 2019 retrospective study of 318 hospitalized patients showed that substituting detemir with glargine on a 1:1 basis did not adversely affect glycemic control or increase hypoglycemia. 9 This supports the safety of unit-for-unit conversion in both inpatient and outpatient settings.